Seraxis
Biotechnology Research in United States
Overview
Seraxis is bringing transformative therapies to the millions of people worldwide struggling with the management of insulin-requiring diabetes and the associated life-threatening complications. Seraxis’ lead program, SR-02, is a novel islet replacement therapy for patients of insulin-requiring diabetes with concurrent immunosuppression therapy. This therapy is the foundation of Seraxis follow-on therapies for patients without immune suppression. Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, the T1D Fund and others are investors in Seraxis.
Tagline
Replacement islet cell therapy for the functional cure of diabetes
EMPLOYEES
11-50 employees
FOUNDED
2013
HQ
Germantown, Maryland
TYPE
Privately Held
Location
- Street
- 20400 Century Blvd
- City
- Germantown
- Region
- Maryland
- Postal code
- 20874
- Country
- United States
Email patterns
See email patterns for Seraxis
Address formats, how often each is used and the mail provider.
Start for freeTrade fairs
FAQ
What is the company name?
seraxis.com is the website of Seraxis.
What is the industry of the company?
Seraxis (seraxis.com) is in the Biotechnology Research industry.
What products and services does the company offer?
Seraxis (seraxis.com) lists these specialties: Cell therapy, Regenerative medicine, Stem cells, Type 1 Diabetes, Organ replacement, Functional endocrine pancreas, and Off-the-shelf implants.
When was the company founded?
Seraxis (seraxis.com) was founded in 2013.
How many employees does the company have?
Seraxis (seraxis.com) has 11-50 employees.
What is the company type?
The company type of Seraxis (seraxis.com) is Privately Held.
Where is the company headquartered?
Seraxis (seraxis.com) is headquartered in Germantown, Maryland.
What is the address of the company?
The address of Seraxis (seraxis.com) is 20400 Century Blvd, Germantown, Maryland, 20874, United States.
What are the social media accounts of the company?
The social media account of Seraxis (seraxis.com) is LinkedIn.
Social media